Brigimadlin (BI 907828): MDM2-p53 antagonist | NSCLC

Through our ongoing research and in partnership with experts in this field, we intend to expand our knowledge about the role of the MDM2-p53 pathway in cancer development. This pathway is an area of high interest for the scientific community as approximately 5-7% of tumors display MDM2 amplifications, including lung cancer and other malignancies, with an incidence of up to 90% in some types of soft tissue sarcoma (STS). BI 907828, our investigational MDM2-p53 antagonist, is a highly potent, oral, small molecule compound that inhibits the interaction between MDM2 and p53, restoring p53 wild type function.